Cagrilintide+semaglutide

CagriSema‌ Composition‌:

‌Cagrilintide‌: A long-acting human glucagon-like peptide-1 (GLP-1) analog that acts on central appetite-regulating pathways. It helps to:

Slow gastric emptying

Increase feelings of fullness, thereby reducing food intake.

Control postprandial blood glucose spikes

‌Semaglutide‌: A GLP-1 receptor agonist approved for the treatment of type 2 diabetes and obesity. It has the following effects:

Increases postprandial insulin release

Reduces glucose production in the liver

Slows the rate at which food leaves the stomach

Reduces feelings of hunger by acting on appetite centers in the brain

Cagrilintide+semaglutide Dosage

CagriSema—as a fixed-dose combination—has an initial dose of 0.25 mg of each drug in the combination, with the dose increased every 4 weeks until the maximum dose of 2.4 mg of each drug is reached by week 16.